GTS
MCID: GLL008
MIFTS: 67

Gilles De La Tourette Syndrome (GTS)

Categories: Mental diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Gilles De La Tourette Syndrome

MalaCards integrated aliases for Gilles De La Tourette Syndrome:

Name: Gilles De La Tourette Syndrome 58 12 26 76 13 15 41 74
Tourette Syndrome 58 12 77 54 26 55 38 30 56 6 44 3 45 15 17
Gilles De La Tourette's Syndrome 77 54 26
Tourette Disorder 58 54 26
Gts 58 26 76
Ts 58 26 3
Chronic Motor and Vocal Tic Disorder 26
Motor-Verbal Tic Disorder 12
Tourette Syndrome; Ts 58
Tourette's Syndrome 54
Tourette's Disease 26
Guinon's Disease 12
Psychogenic Tics 12
Td 26

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
male:female ratio 4:1
onset ages 2 to 14 years


HPO:

33
gilles de la tourette syndrome:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:11119
OMIM 58 137580
KEGG 38 H00862
ICD9CM 36 307.23
MeSH 45 D005879
NCIt 51 C35078
SNOMED-CT 69 39098006 5158005
ICD10 34 F95.2
UMLS 74 C0040517

Summaries for Gilles De La Tourette Syndrome

NIH Rare Diseases : 54 Tourette syndrome is a complex neurological disorder that is characterized by repetitive, sudden, uncontrolled (involuntary) movements and sounds (vocalizations) called tics. Tourette syndrome is named for Georges Gilles de la Tourette, who first described this disorder in 1885. A variety of genetic and environmental factors likely play a role in causing Tourette syndrome. A small number of people with Tourette syndrome have been found to have mutations involving the SLITRK1 gene. The syndrome is believed to be linked to problems in certain areas of the brain, and the chemical substances (dopamine, serotonin, and norepinephrine) that help nerve cells talk to one another. It is estimated that about 1% of the population has Tourette syndrome. Many people with very mild tics may not be aware of them and never seek medical help. Tourette syndrome is four times as likely to occur in boys as in girls. Although Tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the condition experience their worst symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood.

MalaCards based summary : Gilles De La Tourette Syndrome, also known as tourette syndrome, is related to movement disease and tardive dyskinesia, and has symptoms including seizures, tremor and back pain. An important gene associated with Gilles De La Tourette Syndrome is SLITRK1 (SLIT And NTRK Like Family Member 1), and among its related pathways/superpathways are Histidine metabolism and Circadian entrainment. The drugs Clonidine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and cortex, and related phenotypes are sleep disturbance and attention deficit hyperactivity disorder

Disease Ontology : 12 A tic disorder that is characterized by multiple physical (motor) tics and at least one vocal (phonic) tic present for more than a year.

Genetics Home Reference : 26 Tourette syndrome is a complex disorder characterized by repetitive, sudden, and involuntary movements or noises called tics. Tics usually appear in childhood, and their severity varies over time. In most cases, tics become milder and less frequent in late adolescence and adulthood.

OMIM : 58 Tourette syndrome is a neurobehavioral disorder manifest particularly by motor and vocal tics and associated with behavioral abnormalities. Tics are sudden, brief, intermittent, involuntary or semi-voluntary movements (motor tics) or sounds (phonic or vocal tics). They typically consist of simple, coordinated, repetitive movements, gestures, or utterances that mimic fragments of normal behavior. Motor tics may range from simple blinking, nose twitching, and head jerking to more complex throwing, hitting, or making rude gestures. Phonic tics include sniffling, throat clearing, blowing, coughing, echolalia, or coprolalia. Males are affected about 3 times more often than females, and onset usually occurs between 3 and 8 years of age. By age 18 years, more than half of affected individuals are free of tics, but they may persist into adulthood (review by Jankovic, 2001). (137580)

MedlinePlus : 44 If you have Tourette syndrome, you make unusual movements or sounds, called tics. You have little or no control over them. Common tics are throat-clearing and blinking. You may repeat words, spin, or, rarely, blurt out swear words. Tourette syndrome is a disorder of the nervous system. It often occurs with other problems, such as Attention deficit hyperactivity disorder (ADHD) Obsessive-compulsive disorder (OCD) Anxiety Depression The cause of Tourette syndrome is unknown. It is more common in boys than girls. The tics usually start in childhood and may be worst in the early teens. Many people eventually outgrow them. No treatment is needed unless the tics interfere with everyday life. Excitement or worry can make tics worse. Calm, focused activities may make them better. Medicines and talk therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Meet two families and hear about their experiences living with Attention-Deficit/Hyperactivity Disorder and Tourette Syndrome.

NINDS : 55 Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The first symptoms of TS are almost always noticed in childhood.  Some of the more common tics include eye blinking and other vision irregularities, facial grimacing, shoulder shrugging, and head or shoulder jerking. Perhaps the most dramatic and disabling tics are those that result in self-harm such as punching oneself in the face, or vocal tics including coprolalia (uttering swear words) or echolalia (repeating the words or phrases of others).  Many with TS experience additional neurobehavioral problems including inattention, hyperactivity and impulsivity, and obsessive-compulsive symptoms such as intrusive thoughts/worries and repetitive behaviors.

UniProtKB/Swiss-Prot : 76 Gilles de la Tourette syndrome: Neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities.

Wikipedia : 77 Tourette syndrome (TS or simply Tourette''s) is a common neurodevelopmental disorder with onset in... more...

Related Diseases for Gilles De La Tourette Syndrome

Diseases related to Gilles De La Tourette Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 324)
# Related Disease Score Top Affiliating Genes
1 movement disease 31.1 DRD2 SGCE SLC6A3
2 tardive dyskinesia 31.0 COMT DRD2
3 anxiety 30.9 BDNF COMT HTR3A
4 dystonia 30.9 DRD2 DRD5 SGCE SLC6A3
5 pathological gambling 30.6 DRD2 DRD4 SLC6A3
6 mood disorder 30.6 BDNF COMT DRD2 DRD4
7 obsessive-compulsive disorder 30.6 BDNF COMT DRD2 DRD4 HTR3A SGCE
8 impulse control disorder 30.3 DRD2 DRD4 SLITRK1
9 tic disorder 30.2 DRD2 DRD4 DRD5 HDC IMMP2L SLC6A3
10 major depressive disorder 30.2 BDNF COMT DRD2 DRD4 HTR3A SLC6A3
11 restless legs syndrome 30.2 BTBD9 DRD2 SLC6A3
12 early-onset schizophrenia 30.2 BDNF DRD2
13 stuttering 30.1 CNTNAP2 DBH DRD2 SLC6A3
14 traumatic brain injury 30.1 BDNF COMT DRD2
15 brain injury 30.1 BDNF COMT DRD2
16 alcohol abuse 30.0 BDNF DRD2 DRD4
17 attention deficit-hyperactivity disorder 30.0 ADRA2A BDNF CNTNAP2 COMT DBH DRD2
18 substance abuse 30.0 BDNF COMT DBH DRD2 DRD4 DRD5
19 parkinson disease, late-onset 30.0 BDNF COMT DBH DRD2 SLC6A3
20 eating disorder 30.0 BDNF COMT DRD2 SLC6A3
21 oppositional defiant disorder 30.0 COMT DBH DRD2 DRD4 SLC6A3
22 bipolar disorder 29.9 BDNF COMT DRD2 SLC6A3
23 disease of mental health 29.8 BDNF COMT DRD2 DRD4 SLC6A3
24 conduct disorder 29.8 COMT DBH DRD2 DRD4 DRD5 SLC6A3
25 schizophrenia 29.7 BDNF CNTNAP2 COMT DBH DRD2 DRD4
26 alcohol dependence 29.4 BDNF COMT DBH DRD2 DRD4 HTR3A
27 glanzmann thrombasthenia 12.1
28 turner syndrome 12.0
29 virus-associated trichodysplasia spinulosa 11.8
30 trichotillomania 11.6
31 mitochondrial dna depletion syndrome 7 11.4
32 timothy syndrome 11.4
33 cholestasis, benign recurrent intrahepatic, 1 11.3
34 tuberous sclerosis 1 11.3
35 trichostasis spinulosa 11.3
36 temperature sensitivity complementation, cell cycle specific, k12 11.2
37 cone-rod dystrophy and hearing loss 2 11.2
38 modifier, x-linked, for neurofunctional defects 11.1
39 dystonia 11, myoclonic 11.1
40 basal ganglia disease 11.1
41 cholestasis, progressive familial intrahepatic, 1 11.1
42 focal facial dermal dysplasia 3, setleis type 11.1
43 lymphoma, hodgkin, classic 11.1
44 kleefstra syndrome 11.1
45 albinism, oculocutaneous, type ib 11.1
46 tuberous sclerosis 2 11.1
47 perry syndrome 10.9
48 ritscher-schinzel syndrome 1 10.9
49 bile acid synthesis defect, congenital, 2 10.9
50 hyperparathyroidism, neonatal severe 10.9

Graphical network of the top 20 diseases related to Gilles De La Tourette Syndrome:



Diseases related to Gilles De La Tourette Syndrome

Symptoms & Phenotypes for Gilles De La Tourette Syndrome

Human phenotypes related to Gilles De La Tourette Syndrome:

33 (show all 8)
# Description HPO Frequency HPO Source Accession
1 sleep disturbance 33 HP:0002360
2 attention deficit hyperactivity disorder 33 HP:0007018
3 aggressive behavior 33 HP:0000718
4 obsessive-compulsive behavior 33 HP:0000722
5 echolalia 33 HP:0010529
6 self-mutilation 33 HP:0000742
7 motor tics 33 HP:0100034
8 phonic tics 33 HP:0100035

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
sleep disturbance
aggressive behavior
obsessive-compulsive behavior
echolalia
coprolalia
more

Clinical features from OMIM:

137580

UMLS symptoms related to Gilles De La Tourette Syndrome:


seizures, tremor, back pain, pain, headache, syncope, athetosis, chronic pain, sciatica, sleep disturbances, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Gilles De La Tourette Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 ADRA2A BDNF BTBD9 CNTNAP2 COMT DBH
2 growth/size/body region MP:0005378 10.06 BDNF BTBD9 CNTNAP2 DBH DRD2 HDC
3 homeostasis/metabolism MP:0005376 10.03 ADRA2A BDNF BTBD9 COMT DBH DRD2
4 endocrine/exocrine gland MP:0005379 10.02 BDNF COMT DBH DRD2 DRD5 HTR3A
5 nervous system MP:0003631 9.83 ADRA2A BDNF BTBD9 CNTNAP2 COMT DBH
6 integument MP:0010771 9.76 BDNF CNTNAP2 DBH DRD2 HDC HTR3A
7 taste/olfaction MP:0005394 8.92 BDNF CNTNAP2 DRD2 SLC6A3

Drugs & Therapeutics for Gilles De La Tourette Syndrome

Drugs for Gilles De La Tourette Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
3
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
4
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
5
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
6
Guanfacine Approved, Investigational Phase 4,Phase 3 29110-47-2 3519
7
Galantamine Approved Phase 4 357-70-0 9651
8
Ondansetron Approved Phase 4 99614-02-5 4595
9
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
10
Haloperidol Approved Phase 4 52-86-8 3559
11
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
12
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 5324346 3404
13
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
14
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
15 Adrenergic alpha-Agonists Phase 4,Phase 3
16 Antihypertensive Agents Phase 4,Phase 3
17 Autonomic Agents Phase 4,Phase 1
18 Analgesics Phase 4,Phase 3,Phase 2
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
21 Sympatholytics Phase 4
22 Adrenergic Agonists Phase 4,Phase 3
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3
25 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Cholinergic Agents Phase 4,Not Applicable
28 Antidepressive Agents Phase 4,Phase 3,Not Applicable
29 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
31 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Not Applicable
33 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Not Applicable
35 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Serotonin Receptor Agonists Phase 4,Phase 3,Not Applicable
38 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Not Applicable
40 Excitatory Amino Acid Antagonists Phase 4
41 Excitatory Amino Acid Agonists Phase 4
42 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Neuroprotective Agents Phase 4
44 Excitatory Amino Acids Phase 4
45 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2
46 Nootropic Agents Phase 4
47 Cholinesterase Inhibitors Phase 4
48 Gastrointestinal Agents Phase 4
49 Antiemetics Phase 4
50 Antipruritics Phase 4

Interventional clinical trials:

(show top 50) (show all 170)
# Name Status NCT ID Phase Drugs
1 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
2 Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder Recruiting NCT03661983 Phase 4 Aripiprazole (OPC-14597);Placebo
3 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
4 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
5 Comparison of Keppra and Clonidine in the Treatment of Tics Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
6 Guanfacine in Children With Tic Disorders Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
7 Safety Study of Galantamine in Tic Disorders Terminated NCT00226824 Phase 4 galantamine
8 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
9 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
10 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome Unknown status NCT03066193 Phase 3 Dronabinol
11 Pallidal Stimulation and Gilles de la Tourette Syndrome Completed NCT00478842 Phase 3
12 Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01416441 Phase 3 aripiprazole
13 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418352 Phase 3 aripiprazole 52.5 mg;Matching Placebo;Aripiprazole 77.5 mg;Aripiprazole 110 mg
14 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418339 Phase 3 aripiprazole;Placebo
15 Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome Recruiting NCT03487783 Phase 3 Aripiprazole Oral Solution;Placebo Oral Solution
16 Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents. Recruiting NCT03452943 Phase 2, Phase 3 TEV-50717;Placebo
17 Thalamic Deep Brain Stimulation for Tourette Syndrome Completed NCT03958617 Phase 2, Phase 3
18 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
19 Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
20 Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome Terminated NCT00681863 Phase 3 pramipexole 0.125 mg BID;pramipexole 0.0625 mg QD;pramipexole 0.125 mg TID;pramipexole 0.25 mg BID;pramipexole 0.0625 mg BID
21 A Randomized, Placebo-controlled, Tourette Syndrome Study. Completed NCT00206323 Phase 3 Topiramate (drug);placebo/sugar pill
22 A Study to Evaluate the Safety and Tolerability of Long-term Therapy With TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Recruiting NCT03567291 Phase 3 TEV-50717;Placebo
23 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome. Completed NCT00206336 Phase 3 Topiramate (drug)
24 A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome Recruiting NCT03571256 Phase 3 deutetrabenazine Low;deutetrabenazine High;Placebo
25 Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
26 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
27 CANNAbinoids in the Treatment of TICS (CANNA-TICS) Recruiting NCT03087201 Phase 3 nabiximols;placebo
28 Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children Completed NCT00218777 Phase 2, Phase 3
29 Phase III Study of 5LGr to Treat Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
30 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
31 Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome Unknown status NCT02112253 Phase 1, Phase 2
32 Cannabis for Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
33 Selective Microbiota Transplantation for Tourette's Syndrome Recruiting NCT03764748 Phase 1, Phase 2 mini-FMT
34 Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome Terminated NCT01043549 Phase 2
35 Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years Active, not recruiting NCT02102698 Phase 2 Ecopipam
36 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo
37 Safety and Efficacy of Cannabis in Tourette Syndrome Recruiting NCT03247244 Phase 2 Cannabis;Cannabis;Cannabis
38 Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome Terminated NCT03732534 Phase 2 NBI-98854
39 A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome Completed NCT02217007 Phase 2 SNC-102 sustained release tablet
40 Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder Completed NCT01585207 Phase 1, Phase 2 vigabatrin
41 Subthalamic Stimulation in Tourette's Syndrome Completed NCT02619084 Phase 2
42 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome Completed NCT02581865 Phase 2 NBI-98854;Placebo
43 Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome Completed NCT02679079 Phase 2 NBI-98854;Placebo
44 Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder Recruiting NCT03625453 Phase 2 ABX-1431;Placebo
45 VoIP Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
46 Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome Withdrawn NCT01475383 Phase 2 PF-03654746;Placebo;Placebo;PF-03654746
47 Ecopipam Treatment of Tourette Syndrome Completed NCT01244633 Phase 1, Phase 2 Ecopipam
48 A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome Completed NCT01647269 Phase 2
49 Thalamic Deep Brain Stimulation for Tourette Syndrome Completed NCT00311909 Phase 2
50 A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome Not yet recruiting NCT03651726 Phase 2 THX-110 (dronabinol plus PEA);Placebo

Search NIH Clinical Center for Gilles De La Tourette Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: tourette syndrome

Genetic Tests for Gilles De La Tourette Syndrome

Genetic tests related to Gilles De La Tourette Syndrome:

# Genetic test Affiliating Genes
1 Tourette Syndrome 30 HDC SLITRK1

Anatomical Context for Gilles De La Tourette Syndrome

MalaCards organs/tissues related to Gilles De La Tourette Syndrome:

42
Brain, Eye, Cortex, Globus Pallidus, Testes, Bone, Thalamus

Publications for Gilles De La Tourette Syndrome

Articles related to Gilles De La Tourette Syndrome:

(show top 50) (show all 1885)
# Title Authors Year
1
Calcium pyrophosphate dihydrate crystal deposition disease and MRSA septic arthritis of the atlantoaxial joint in a patient with Tourette syndrome. ( 30904893 )
2019
2
Clinical and genetic analysis of children with a dual diagnosis of Tourette syndrome and autism spectrum disorder. ( 30771620 )
2019
3
Association of Tourette Syndrome and Chronic Tic Disorder With Metabolic and Cardiovascular Disorders. ( 30640363 )
2019
4
Robust clinical benefit of multi-target deep brain stimulation for treatment of Gilles de la Tourette syndrome and its comorbidities. ( 30878341 )
2019
5
Single center experience with medical cannabis in Gilles de la Tourette syndrome. ( 30292733 )
2019
6
Corneal cross-linking for keratoconus caused by compulsive eye rubbing in patients with Tourette syndrome: Three case reports. ( 31096492 )
2019
7
Self-induced lens subluxation with avulsion of ciliary processes in Tourette Syndrome. ( 31008412 )
2019
8
Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder. ( 30700759 )
2019
9
Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report. ( 30899317 )
2019
10
Tourette syndrome: Clinical benefit with unilateral stimulation after bilateral pallidal implant. ( 30801769 )
2019
11
Gastrodin attenuates neuroinflammation in DOI-induce Tourette syndrome in rats. ( 30790395 )
2019
12
Common (Genetic) Links Between Clinics and the Community: New Evidence From a Tourette Syndrome Polygenic Score. ( 30665500 )
2019
13
The role of sensory sensitivity in predicting food selectivity and food preferences in children with Tourette syndrome. ( 30634006 )
2019
14
CM-Pf deep brain stimulation and the long term management of motor and psychiatric symptoms in a case of Tourette syndrome. ( 30612913 )
2019
15
Polygenic Risk Scores Derived From a Tourette Syndrome Genome-wide Association Study Predict Presence of Tics in the Avon Longitudinal Study of Parents and Children Cohort. ( 30424865 )
2019
16
Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report. ( 30058466 )
2019
17
Social adjustment experiences of adolescents with Tourette syndrome. ( 29893437 )
2019
18
Exploring the clinical outcomes after deep brain stimulation in Tourette syndrome. ( 31103958 )
2019
19
A superior ability to suppress fast inappropriate responses in children with Tourette syndrome is further improved by prospect of reward. ( 31103639 )
2019
20
Motor Timing in Tourette Syndrome: The Effect of Movement Lateralization and Bimanual Coordination. ( 31080434 )
2019
21
Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. ( 31061209 )
2019
22
Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. ( 31061208 )
2019
23
Progress in Pharmacological and Surgical Management of Tourette Syndrome and Other Chronic Tic Disorders. ( 31045720 )
2019
24
The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. ( 30977108 )
2019
25
Globus Pallidus Internus electrical high frequency stimulation modulates Dopaminergic activity in the striatal of the Tourette syndrome's rat model. ( 30959252 )
2019
26
Concordance of genetic variation that increases risk for tourette syndrome and that influences its underlying neurocircuitry. ( 30902966 )
2019
27
A Bayesian Account of the Sensory-Motor Interactions Underlying Symptoms of Tourette Syndrome. ( 30890965 )
2019
28
Correction: Brain structure in pediatric Tourette syndrome. ( 30842575 )
2019
29
Treating Tourette syndrome without drugs. ( 30828939 )
2019
30
Korean adults' beliefs about and social distance toward attention-deficit hyperactivity disorder, Tourette syndrome, and autism spectrum disorder. ( 30212793 )
2018
31
Implicit sequence learning in young people with Tourette syndrome with and without co-occurring attention-deficit/hyperactivity disorder. ( 29972622 )
2018
32
A Randomized Controlled Trial Comparing Behavioral, Educational, and Pharmacological Treatments in Youths With Chronic Tic Disorder or Tourette Syndrome. ( 29636706 )
2018
33
Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data. ( 30497215 )
2018
34
Distinctive tics suppression network in Gilles de la Tourette syndrome distinguished from suppression of natural urges using multimodal imaging. ( 30268027 )
2018
35
The neuropsychiatry of Gilles de la Tourette syndrome: The état de l'art. ( 30098800 )
2018
36
Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. ( 30090843 )
2018
37
Phenomenology and Clinical Correlates of Stimulus-Bound Tics in Gilles de la Tourette Syndrome. ( 29988443 )
2018
38
Altered perception-action binding modulates inhibitory control in Gilles de la Tourette syndrome. ( 29924402 )
2018
39
Gilles de la Tourette syndrome as a paradigmatic neuropsychiatric disorder. ( 29781408 )
2018
40
Efficacy of a Gluten-Free Diet in the Gilles de la Tourette Syndrome: A Pilot Study. ( 29735930 )
2018
41
Aripiprazole in treatment of Gilles de la Tourette syndrome - New therapeutic option. ( 29154107 )
2018
42
Heterozygous deletion of SCN2A and SCN3A in a patient with autism spectrum disorder and Tourette syndrome: a case report. ( 30071822 )
2018
43
Seroprevalance Anti-Toxoplasma gondii antibodies in children and adolescents with tourette syndrome/chronic motor or vocal tic disorder: A case-control study. ( 29554545 )
2018
44
Neural correlates of prediction violations in boys with Tourette syndrome: Evidence from harmonic expectancy. ( 28010171 )
2018
45
Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. ( 28651666 )
2018
46
Combining Disrupted and Discriminative Topological Properties of Functional Connectivity Networks as Neuroimaging Biomarkers for Accurate Diagnosis of Early Tourette Syndrome Children. ( 28478510 )
2018
47
Deep brain stimulation for Tourette syndrome: a single-center series. ( 28387621 )
2018
48
Thalamic Deep Brain Stimulation for Refractory Tourette Syndrome: Clinical Evidence for Increasing Disbalance of Therapeutic Effects and Side Effects at Long-Term Follow-Up. ( 28102636 )
2018
49
Choline acetyltransferase may contribute to the risk of Tourette syndrome: Combination of family-based analysis and case-control study. ( 28090804 )
2018
50
Effects of orthopedic treatment using temporomandibular joint balancing appliance (TBA) at improving the symptoms of tic/Tourette syndrome: case report. ( 30591893 )
2018

Variations for Gilles De La Tourette Syndrome

ClinVar genetic disease variations for Gilles De La Tourette Syndrome:

6 (show top 50) (show all 118)
# Gene Variation Type Significance SNP ID Assembly Location
1 SLITRK1 NM_052910.2(SLITRK1): c.1264del (p.Leu422Phefs) deletion Pathogenic rs193302861 GRCh37 Chromosome 13, 84454379: 84454379
2 SLITRK1 NM_052910.2(SLITRK1): c.1264del (p.Leu422Phefs) deletion Pathogenic rs193302861 GRCh38 Chromosome 13, 83880244: 83880244
3 SLITRK1 NM_052910.2(SLITRK1): c.*689G> A single nucleotide variant Pathogenic rs191284403 GRCh37 Chromosome 13, 84452863: 84452863
4 SLITRK1 NM_052910.2(SLITRK1): c.*689G> A single nucleotide variant Pathogenic rs191284403 GRCh38 Chromosome 13, 83878728: 83878728
5 HDC NM_002112.3(HDC): c.951G> A (p.Trp317Ter) single nucleotide variant Pathogenic rs267606861 GRCh38 Chromosome 15, 50252520: 50252520
6 HDC NM_002112.3(HDC): c.951G> A (p.Trp317Ter) single nucleotide variant Pathogenic rs267606861 GRCh37 Chromosome 15, 50544717: 50544717
7 SLITRK1 NM_052910.2(SLITRK1): c.*2043delT deletion Likely benign rs66938370 GRCh37 Chromosome 13, 84451509: 84451509
8 SLITRK1 NM_052910.2(SLITRK1): c.*2043delT deletion Likely benign rs66938370 GRCh38 Chromosome 13, 83877374: 83877374
9 SLITRK1 NM_052910.2(SLITRK1): c.*1882A> T single nucleotide variant Uncertain significance rs886050327 GRCh38 Chromosome 13, 83877535: 83877535
10 SLITRK1 NM_052910.2(SLITRK1): c.*1882A> T single nucleotide variant Uncertain significance rs886050327 GRCh37 Chromosome 13, 84451670: 84451670
11 SLITRK1 NM_052910.2(SLITRK1): c.*1572C> G single nucleotide variant Uncertain significance rs368937569 GRCh38 Chromosome 13, 83877845: 83877845
12 SLITRK1 NM_052910.2(SLITRK1): c.*1572C> G single nucleotide variant Uncertain significance rs368937569 GRCh37 Chromosome 13, 84451980: 84451980
13 SLITRK1 NM_052910.2(SLITRK1): c.*1160G> A single nucleotide variant Likely benign rs9602286 GRCh38 Chromosome 13, 83878257: 83878257
14 SLITRK1 NM_052910.2(SLITRK1): c.*1160G> A single nucleotide variant Likely benign rs9602286 GRCh37 Chromosome 13, 84452392: 84452392
15 SLITRK1 NM_052910.2(SLITRK1): c.*1149dupT duplication Uncertain significance rs886050328 GRCh38 Chromosome 13, 83878268: 83878268
16 SLITRK1 NM_052910.2(SLITRK1): c.*1149dupT duplication Uncertain significance rs886050328 GRCh37 Chromosome 13, 84452403: 84452403
17 SLITRK1 NM_052910.2(SLITRK1): c.*1134T> C single nucleotide variant Likely benign rs3737193 GRCh38 Chromosome 13, 83878283: 83878283
18 SLITRK1 NM_052910.2(SLITRK1): c.*1134T> C single nucleotide variant Likely benign rs3737193 GRCh37 Chromosome 13, 84452418: 84452418
19 SLITRK1 NM_052910.2(SLITRK1): c.*575C> T single nucleotide variant Uncertain significance rs886050329 GRCh38 Chromosome 13, 83878842: 83878842
20 SLITRK1 NM_052910.2(SLITRK1): c.*575C> T single nucleotide variant Uncertain significance rs886050329 GRCh37 Chromosome 13, 84452977: 84452977
21 SLITRK1 NM_052910.2(SLITRK1): c.913C> G (p.Pro305Ala) single nucleotide variant Uncertain significance rs867766209 GRCh38 Chromosome 13, 83880595: 83880595
22 SLITRK1 NM_052910.2(SLITRK1): c.913C> G (p.Pro305Ala) single nucleotide variant Uncertain significance rs867766209 GRCh37 Chromosome 13, 84454730: 84454730
23 SLITRK1 NM_052910.2(SLITRK1): c.-245dupT duplication Uncertain significance rs771177138 GRCh37 Chromosome 13, 84455887: 84455887
24 SLITRK1 NM_052910.2(SLITRK1): c.-245dupT duplication Uncertain significance rs771177138 GRCh38 Chromosome 13, 83881752: 83881752
25 SLITRK1 NM_052910.2(SLITRK1): c.-270delT deletion Uncertain significance rs886050341 GRCh37 Chromosome 13, 84455912: 84455912
26 SLITRK1 NM_052910.2(SLITRK1): c.-270delT deletion Uncertain significance rs886050341 GRCh38 Chromosome 13, 83881777: 83881777
27 SLITRK1 NM_052910.2(SLITRK1): c.-584T> G single nucleotide variant Uncertain significance rs886050344 GRCh37 Chromosome 13, 84456226: 84456226
28 SLITRK1 NM_052910.2(SLITRK1): c.-584T> G single nucleotide variant Uncertain significance rs886050344 GRCh38 Chromosome 13, 83882091: 83882091
29 SLITRK1 NM_052910.2(SLITRK1): c.-729G> C single nucleotide variant Uncertain significance rs774658734 GRCh38 Chromosome 13, 83882236: 83882236
30 SLITRK1 NM_052910.2(SLITRK1): c.-729G> C single nucleotide variant Uncertain significance rs774658734 GRCh37 Chromosome 13, 84456371: 84456371
31 SLITRK1 NM_052910.2(SLITRK1): c.*2186T> A single nucleotide variant Uncertain significance rs886050326 GRCh37 Chromosome 13, 84451366: 84451366
32 SLITRK1 NM_052910.2(SLITRK1): c.*2186T> A single nucleotide variant Uncertain significance rs886050326 GRCh38 Chromosome 13, 83877231: 83877231
33 SLITRK1 NM_052910.2(SLITRK1): c.*2087T> C single nucleotide variant Uncertain significance rs182027644 GRCh37 Chromosome 13, 84451465: 84451465
34 SLITRK1 NM_052910.2(SLITRK1): c.*2087T> C single nucleotide variant Uncertain significance rs182027644 GRCh38 Chromosome 13, 83877330: 83877330
35 SLITRK1 NM_052910.2(SLITRK1): c.*2042T> A single nucleotide variant Likely benign rs1046202 GRCh37 Chromosome 13, 84451510: 84451510
36 SLITRK1 NM_052910.2(SLITRK1): c.*2042T> A single nucleotide variant Likely benign rs1046202 GRCh38 Chromosome 13, 83877375: 83877375
37 SLITRK1 NM_052910.2(SLITRK1): c.*1944A> G single nucleotide variant Uncertain significance rs543615109 GRCh37 Chromosome 13, 84451608: 84451608
38 SLITRK1 NM_052910.2(SLITRK1): c.*1944A> G single nucleotide variant Uncertain significance rs543615109 GRCh38 Chromosome 13, 83877473: 83877473
39 SLITRK1 NM_052910.2(SLITRK1): c.*1313C> G single nucleotide variant Uncertain significance rs140472390 GRCh38 Chromosome 13, 83878104: 83878104
40 SLITRK1 NM_052910.2(SLITRK1): c.*1313C> G single nucleotide variant Uncertain significance rs140472390 GRCh37 Chromosome 13, 84452239: 84452239
41 SLITRK1 NM_052910.2(SLITRK1): c.*649A> G single nucleotide variant Uncertain significance rs57857456 GRCh38 Chromosome 13, 83878768: 83878768
42 SLITRK1 NM_052910.2(SLITRK1): c.*649A> G single nucleotide variant Uncertain significance rs57857456 GRCh37 Chromosome 13, 84452903: 84452903
43 SLITRK1 NM_052910.2(SLITRK1): c.*23G> A single nucleotide variant Uncertain significance rs200497030 GRCh38 Chromosome 13, 83879394: 83879394
44 SLITRK1 NM_052910.2(SLITRK1): c.*23G> A single nucleotide variant Uncertain significance rs200497030 GRCh37 Chromosome 13, 84453529: 84453529
45 SLITRK1 NM_052910.2(SLITRK1): c.-240delG deletion Uncertain significance rs886050337 GRCh37 Chromosome 13, 84455882: 84455882
46 SLITRK1 NM_052910.2(SLITRK1): c.-240delG deletion Uncertain significance rs886050337 GRCh38 Chromosome 13, 83881747: 83881747
47 SLITRK1 NM_052910.2(SLITRK1): c.-241dupT duplication Uncertain significance rs886050338 GRCh37 Chromosome 13, 84455883: 84455883
48 SLITRK1 NM_052910.2(SLITRK1): c.-241dupT duplication Uncertain significance rs886050338 GRCh38 Chromosome 13, 83881748: 83881748
49 SLITRK1 NM_052910.2(SLITRK1): c.-589A> G single nucleotide variant Uncertain significance rs886050345 GRCh37 Chromosome 13, 84456231: 84456231
50 SLITRK1 NM_052910.2(SLITRK1): c.-266delA deletion Uncertain significance rs886050340 GRCh37 Chromosome 13, 84455908: 84455908

Copy number variations for Gilles De La Tourette Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 60595 11 88300000 92800000 Copy number GRM5 Tourette syndrome
2 97401 16 1 7900000 Copy number A2BP1 Tourette syndrome
3 107550 17 15900000 22100000 Microdeletion Tourette syndrome
4 161233 22 17900000 22200000 Duplication COMT Tourette syndrome
5 204047 6 105500000 114600000 Copy number NKAIN2 Tourette syndrome
6 218083 7 107400000 127100000 Copy number IMMP2L Tourette syndrome
7 221370 7 143100000 147900000 Copy number CNTNAP2 Tourette syndrome
8 222485 7 152600000 155100000 Copy number DPP6 Tourette syndrome
9 257157 X 1 4300000 Deletion NLGN4 Tourette syndrome

Expression for Gilles De La Tourette Syndrome

Search GEO for disease gene expression data for Gilles De La Tourette Syndrome.

Pathways for Gilles De La Tourette Syndrome

Pathways related to Gilles De La Tourette Syndrome according to KEGG:

38
# Name Kegg Source Accession
1 Histidine metabolism hsa00340

GO Terms for Gilles De La Tourette Syndrome

Cellular components related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.81 ADRA2A DRD2 DRD4 DRD5 HTR3A HTR3B
2 glutamatergic synapse GO:0098978 9.78 DRD2 DRD4 HTR3A SLITRK1
3 dendrite GO:0030425 9.73 BDNF CNTNAP2 COMT DRD2 DRD4 SGCE
4 integral component of presynaptic membrane GO:0099056 9.58 DRD2 HTR3A SLC6A3
5 integral component of postsynaptic membrane GO:0099055 9.54 DRD2 HTR3A SLC6A3
6 integral component of membrane GO:0016021 9.53 AADAC ADRA2A CNTNAP2 COMT DBH DRD2
7 dopaminergic synapse GO:0098691 9.43 DRD2 SLC6A3
8 axon GO:0030424 9.43 BDNF CNTNAP2 COMT DRD2 HTR3A SLC6A3
9 serotonin-activated cation-selective channel complex GO:1904602 9.32 HTR3A HTR3B
10 membrane GO:0016020 10.33 AADAC ADRA2A CNTNAP2 COMT DBH DRD2

Biological processes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.94 COMT DRD2 SLC1A3 SLC6A3
2 response to ethanol GO:0045471 9.82 DRD2 HTR3A SLC6A3
3 locomotory behavior GO:0007626 9.78 DBH DRD2 SLC6A3
4 synapse assembly GO:0007416 9.72 BDNF DRD2 SLITRK1
5 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.66 ADRA2A DRD2
6 behavioral response to cocaine GO:0048148 9.66 DRD2 DRD4
7 response to pain GO:0048265 9.65 COMT DBH
8 transmission of nerve impulse GO:0019226 9.65 CNTNAP2 DRD5
9 dopamine receptor signaling pathway GO:0007212 9.64 DRD2 DRD4
10 negative regulation of protein secretion GO:0050709 9.63 DRD2 DRD4
11 response to iron ion GO:0010039 9.63 DRD2 SLC6A3
12 chemical synaptic transmission GO:0007268 9.63 DBH DRD4 DRD5 HTR3A HTR3B SLC1A3
13 synaptic transmission, dopaminergic GO:0001963 9.62 DRD2 DRD5
14 striatum development GO:0021756 9.62 CNTNAP2 DRD2
15 prepulse inhibition GO:0060134 9.61 DRD2 SLC6A3
16 associative learning GO:0008306 9.61 DBH DRD2 DRD5
17 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.6 DRD2 DRD4
18 regulation of dopamine metabolic process GO:0042053 9.59 DRD4 SLC6A3
19 adenohypophysis development GO:0021984 9.58 DRD2 SLC6A3
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.58 DRD2 DRD4
21 adult behavior GO:0030534 9.58 CNTNAP2 DRD2 SLITRK1
22 serotonin receptor signaling pathway GO:0007210 9.57 HTR3A HTR3B
23 neurotransmitter uptake GO:0001504 9.56 SLC1A3 SLC6A3
24 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.54 DRD2 DRD5
25 dopamine metabolic process GO:0042417 9.54 COMT DRD2 DRD4
26 auditory behavior GO:0031223 9.52 DRD2 SLC1A3
27 catecholamine biosynthetic process GO:0042423 9.51 DBH HDC
28 behavioral response to ethanol GO:0048149 9.5 DBH DRD2 DRD4
29 fear response GO:0042596 9.49 DBH DRD4
30 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD2 DRD4
31 response to histamine GO:0034776 9.46 DRD2 DRD4
32 dopamine catabolic process GO:0042420 9.43 COMT DBH SLC6A3
33 response to cocaine GO:0042220 9.26 DRD2 DRD5 HTR3A SLC6A3
34 response to amphetamine GO:0001975 8.92 DBH DRD2 DRD4 DRD5

Molecular functions related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.58 DRD2 DRD4 SLC6A3
2 adrenergic receptor activity GO:0004935 9.43 ADRA2A DRD2
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD2 DRD4
4 epinephrine binding GO:0051379 9.32 ADRA2A DRD4
5 norepinephrine binding GO:0051380 9.26 ADRA2A DRD4
6 serotonin-gated cation-selective channel activity GO:0022850 9.16 HTR3A HTR3B
7 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
8 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Gilles De La Tourette Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....